2021
DOI: 10.24953/turkjped.2021.02.016
|View full text |Cite
|
Sign up to set email alerts
|

Brown Vialetto Van Laere syndrome: presenting with left ventricular non-compaction and mimicking mitochondrial disorders

Abstract: Background. Brown-Vialetto-Van Laere syndrome (BVVLS) is a rare, treatable neurodegenerative disorder with a variable clinical presentation, caused by mutations in three different riboflavin transporter genes.Case. An 11-year-old-boy presented with respiratory insufficiency and a rapidly progressive muscle weakness. He was the fifth child of a consanguineous marriage with a medical history of hearing loss. He was peripherally week with a reduced muscle tone. Upper extremity muscles were effected more than lowe… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(1 citation statement)
references
References 12 publications
0
1
0
Order By: Relevance
“…A summary of the articles that reported follow-up data in each of the domains is shown in Table S1. Forty-seven of those patients had RTD2 due to biallelic mutations in SLC52A2, [2][3][4]12,[14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33] 46 had RTD3 due to biallelic mutations in SLC52A3 18,20,24,27,31, and one patient had a mutation in both SLC52A2 and SLC52A3. 58 Seventy-six of the 94 patients (80.9%) showed an overall improvement after riboflavin supplementation, and the remaining (19.1%) were stable after riboflavin supplementation.…”
Section: Overall Responsementioning
confidence: 99%
“…A summary of the articles that reported follow-up data in each of the domains is shown in Table S1. Forty-seven of those patients had RTD2 due to biallelic mutations in SLC52A2, [2][3][4]12,[14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33] 46 had RTD3 due to biallelic mutations in SLC52A3 18,20,24,27,31, and one patient had a mutation in both SLC52A2 and SLC52A3. 58 Seventy-six of the 94 patients (80.9%) showed an overall improvement after riboflavin supplementation, and the remaining (19.1%) were stable after riboflavin supplementation.…”
Section: Overall Responsementioning
confidence: 99%